Facebook Twitter LinkedIn Google Plus RSS

Arno, J&J subsidiary to collaborate on development of diagnostic test

By ,

Flemington-based Arno Therapeutics Inc., a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has signed an agreement with Raritan-based Veridex LLC, a Johnson & Johnson subsidiary, to develop a diagnostic test to help identify patients whom could potentially benefit from certain cancer treatments.

According to the announcement, the collaboration will allow Arno to utilize Veridex’s proprietary Cellsearch technology to capture, isolate and count circulating tumor cells with a high level of sensitivity and specificity. Terms were not disclosed.

Also Popular on NJBIZ

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy